Identification of lactic acid bacteria strains modulating incretin hormone secretion and gene expression in enteroendocrine cells

Glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) are incretin hormones released from intestinal enteroendocrine (EE) cells and have well-established glucose-lowering actions. Lactic acid bacteria (LAB) colonise the human intestine, but it is unknown whether LAB and EE cells interact. Acute co-culture of LAB with EE cells showed that certain LAB strains elicit GLP-1 and GIP secretion (13-194-fold) and upregulate their gene expression. LAB-induced incretin hormone secretion did not appear to involve nutrient mechanisms, nor was there any evidence of cytolysis. Instead PCR array studies implicated signalling agents of the toll-like receptor system, e.g. adaptor protein MyD88 was decreased 23-fold and cell surface antigen CD14 was increased 17-fold. Mechanistic studies found that blockade of MyD88 triggered significant GLP-1 secretion. Furthermore, blocking of CD14 completely attenuated LAB-induced secretion. A recent clinical trial clearly shows that LAB have potential for alleviating type 2 diabetes, and further characterisation of this bioactivity is warranted.

Challenges to undertaking randomised trials with looked after children in social care settings

Background: Randomised controlled trials (RCTs) are widely viewed as the gold standard for assessing effectiveness in health research; however many researchers and practitioners believe that RCTs are inappropriate and un-doable in social care settings, particularly in relation to looked after children. The aim of this article is to describe the challenges faced in conducting a pilot study and phase II RCT of a peer mentoring intervention to reduce teenage pregnancy in looked after children in a social care setting.

Methods: Interviews were undertaken with social care professionals and looked after children, and a survey conducted with looked after children, to establish the feasibility and acceptability of the intervention and research design.

Results: Barriers to recruitment and in managing the intervention were identified, including social workers acting as informal gatekeepers; social workers concerns and misconceptions about the recruitment criteria and the need for and purpose of randomisation; resource limitations, which made it difficult to prioritise research over other demands on their time and difficulties in engaging and retaining looked after children in the study.

Conclusions: The relative absence of a research infrastructure and culture in social care and the lack of research support funding available for social care agencies, compared to health organisations, has implications for increasing evidence-based practice in social care settings, particularly in this very vulnerable group of young people.

Oral rehabilitation for partially dentate elders: a qualitative analysis

Aims: This study aimed to gain insight into patient’s perceptions of natural tooth loss and explored their experiences of oral rehabilitation according to a functionally orientated approach (SDA) and Removable Partial Dentures (RPD).
Study Design: For this qualitative study, a purposive sample of 15 partially dentate older patients
were recruited from Cork Dental School and Hospital. These patients had previously participated in a randomised controlled clinical trial (RCT) where they were provided with either SDA treatment using adhesive bridgework or provided with Cobalt Chromium framework RPDs. In- depth interviews were undertaken and thematic analysis was utilised to interpret the data.
Results: The findings of this study indicated strong satisfaction with SDA treatment. Patients referred to the ease in which they adapted to the adhesive prostheses as they were “lightweight”, “neat” and “fixed”. Irrespective of treatment option, patients indicated that they felt
their new prostheses were durable and an improvement on previous treatments. Most patients indicated that, previous to the RCT, they had not attended a general dentist for a number of years and only then for acute issues. They had concerns that treatment which was provided to them as part of the RCT would not be available to them in primary care. Interestingly, although they do not want their condition to dis-improve, if their prostheses failed they stated that they would not seek alternative treatment but would revert back
to adopting previous coping mechanisms.
Conclusion: This study illustrates that partially dentate older patients were very satisfied with oral rehabilitation according to a functionally orientated approach. Unfortunately they did not believe that this treatment would currently be made available to them in a primary care setting.

Genomic markers for decision making:What is preventing us from using markers?

The advent of novel genomic technologies that enable the evaluation of genomic alterations on a genome-wide scale has significantly altered the field of genomic marker research in solid tumors. Researchers have moved away from the traditional model of identifying a particular genomic alteration and evaluating the association between this finding and a clinical outcome measure to a new approach involving the identification and measurement of multiple genomic markers simultaneously within clinical studies. This in turn has presented additional challenges in considering the use of genomic markers in oncology, such as clinical study design, reproducibility and interpretation and reporting of results. This Review will explore these challenges, focusing on microarray-based gene-expression profiling, and highlights some common failings in study design that have impacted on the use of putative genomic markers in the clinic. Despite these rapid technological advances there is still a paucity of genomic markers in routine clinical use at present. A rational and focused approach to the evaluation and validation of genomic markers is needed, whereby analytically validated markers are investigated in clinical studies that are adequately powered and have pre-defined patient populations and study endpoints. Furthermore, novel adaptive clinical trial designs, incorporating putative genomic markers into prospective clinical trials, will enable the evaluation of these markers in a rigorous and timely fashion. Such approaches have the potential to facilitate the implementation of such markers into routine clinical practice and consequently enable the rational and tailored use of cancer therapies for individual patients. © 2010 Macmillan Publishers Limited. All rights reserved.

Disordered sleep and myopia risk among Chinese children

PURPOSE: Disordered sleep and myopia are increasingly prevalent among Chinese children. Similar pathways may be involved in regulation of both sleep cycles and eye growth. We therefore sought to examine the association between disordered sleep and myopia in this group. METHODS: Urban primary school children participating in a clinical trial on myopia and outdoor activity underwent automated cycloplegic refraction with subjective refinement. Parents answered questions about children's sleep duration, sleep disorders (Children's Sleep Habits Questionnaire [CSHQ]), near work and time spent outdoors. RESULTS: Among 1970 children, 1902 (96.5%, mean [standard deviation SD] age 9.80 [0.44] years, 53.1% boys) completed refraction and questionnaires. Myopia < = -0.50 Diopters was present in both eyes of 588 (30.9%) children (1329/3804 = 34.9% of eyes) and 1129 children (59.4%) had abnormal CSHQ scores (> 41). In logistic regression models by eye, odds of myopia < = -0.50D increased with worse CSHQ score (Odds Ratio [OR] 1.01 per point, 95% Confidence Interval [CI] [1.001, 1.02], P = 0.014) and more night-time sleep (OR 1.02, 95% CI [1.01, 1.04, P = 0.002], while male sex (OR 0.82, 95% CI [0.70, 0.95], P = 0.008) and time outdoors (OR = 0.97, 95% CI [0.95, 0.99], P = 0.011) were associated with less myopia. The association between sleep duration and myopia was not significant (p = 0.199) for total (night + midday) sleep. CONCLUSIONS: Myopia and disordered sleep were both common in this cohort, but we did not find consistent evidence for an association between the two. TRIAL REGISTRATION: clinicaltrials.gov NCT00848900.

MErCuRIC1: A Phase I study of MEK1/2 inhibitor PD-0325901 with cMET inhibitor crizotinib in RASMT and RASWT (with aberrant c-MET) metastatic colorectal cancer (mCRC) patients.

Background: RAS is mutated (RASMT) in ~55% of mCRC, and phase III studies have shown that patients harbouring RAS mutations do not benefit from anti-EGFR MoAbs. In addition, ~50% of RAS Wild Type (RASWT) will not benefit from the addition of an EGFR MoAb to standard chemotherapy. Hence, novel treatment strategies are urgently needed for RASMT and > 50% of RASWT mCRC patients. c-MET is overexpressed in ~50-60%, amplified in ~2-3% and mutated in ~3-5% of mCRC. Recent preclinical studies have shown that c-MET is an important mediator of resistance to MEK inhibitors (i) in RASMT mCRC, and that combined MEKi/METi resulted in synergistic reduction in tumour growth in RASMT xenograft models (1). A number of recent studies have highlighted the role of c-MET in mediating primary/secondary resistance to anti-EGFR MoAbs in mCRC, suggesting that patient with RASWT tumours with aberrant c-MET (RASWT/c-MET+) may benefit from anti-c-MET targeted therapies (2). These preclinical data supported the further clinical evaluation of combined MEKi/METi treatment in RASMT and RASWT CRC patients with aberrant c-MET signalling (overexpression, amplification or mutation; RASWT/c-MET+). Methods: MErCuRIC1 is a phase I combination study of METi crizotinib with MEKi PD-0325901. The dose escalation phase, utilizing a rolling six design, recruits 12-24 patients with advanced solid tumours and aims to assess safety/toxicity of combination, recommended phase II (RPII) dose, pharmacokinetics (PK) and pharmacodynamics (PD) (pERK1/2 in PBMC and tumour; soluble c-MET). In the dose expansion phase an additional 30-42 RASMT and RASWT/c-MET mCRC patients with biopsiable disease will be treated at the RPII dose to further evaluate safety, PK, PD and treatment response. In the dose expansion phase additional biopsy and blood samples will be obtained to define mechanisms of response/resistance to crizotinib/PD-0325901 therapy. Enrolment into the dose escalation phase began in December 2014 with cohort 1 still ongoing. EudraCT registry number: 2014-000463-40. (1) Van Schaeybroeck S et al. Cell Reports 2014;7(6):1940-55; (2) Bardelli A et al. Cancer Discov 2013;3(6):658-73. Clinical trial information: 2014-000463-40.

Potential public health impact of Age-Related Eye Disease Study results: AREDS report no. 11.

OBJECTIVE:

To estimate the potential public health impact of the findings of the Age-Related Eye Disease Study (AREDS) on reducing the number of persons developing advanced age-related macular degeneration (AMD) during the next 5 years in the United States.

METHODS:

The AREDS clinical trial provides estimates of AMD progression rates and of reduction in risk of developing advanced AMD when a high-dose nutritional supplement of antioxidants and zinc is used. These results are applied to estimates of the US population at risk, to estimate the number of people who would potentially avoid advanced AMD during 5 years if those at risk were to take a supplement such as that used in AREDS.

RESULTS:

An estimated 8 million persons at least 55 years old in the United States have monocular or binocular intermediate AMD or monocular advanced AMD. They are considered to be at high risk for advanced AMD and are those for whom the AREDS formulation should be considered. Of these people, 1.3 million would develop advanced AMD if no treatment were given to reduce their risk. If all of these people at risk received supplements such as those used in AREDS, more than 300,000 (95% confidence interval, 158,000-487,000) of them would avoid advanced AMD and any associated vision loss during the next 5 years.

CONCLUSION:

If people at high risk for advanced AMD received supplements such as those suggested by AREDS results, the potential impact on public health in the United States would be considerable during the next 5 years.

The effects of sevoflurane and ketamine on intraocular pressure in children during examination under anesthesia

PURPOSE: We studied the effects on intraocular pressure (IOP) of anesthesia administered during examination under anesthesia (EUA) in children. DESIGN: Randomized clinical trial. METHODS: This randomized trial compared IOP after inhaled sevoflurane gas to that after intramuscular ketamine hydrochloride in children undergoing EUA. IOP was measured in 30 eyes with TonoPen XL (Mentor, Inc, Norwell, Massachusetts, USA) as soon as possible after anesthesia induction (T1) and two, four, six, and eight minutes thereafter. At the same times, we recorded systolic and diastolic blood pressure (SBP, DBP) and heart rate (HR). RESULTS: Compared with the mean IOP at T1, IOP in the sevoflurane group was significantly lower for all measurements from two to eight minutes thereafter (mean decrease in IOP: two minutes = 12%, four minutes = 19%; six minutes = 19%; eight minutes = 17%, all P < or = .01). In the ketamine group, mean IOP was not significantly changed from T1 through six minutes, whereas at eight minutes, it was 7% lower (P = .03). SBP and DBP were significantly lower for sevoflurane than for ketamine at all measurements from two minutes onward, and HR was lower for sevoflurane than for ketamine at two, four, and six minutes. CONCLUSIONS: IOP measured after ketamine sedation is more likely to represent the awake IOP than that after sevoflurane anesthesia. Changes in SBP, DBP, and HR caused by sevoflurane suggest that hemodynamic alterations may underlie its effects on IOP.

The design and implementation of a study to investigate the effectiveness of community vs hospital eye service follow-up for patients with neovascular age-related macular degeneration with quiescent disease

Introduction
Standard treatment for neovascular age-related macular degeneration (nAMD) is intravitreal injections of anti-VEGF drugs. Following multiple injections, nAMD lesions often become quiescent but there is a high risk of reactivation, and regular review by hospital ophthalmologists is the norm. The present trial examines the feasibility of community optometrists making lesion reactivation decisions.

Methods
The Effectiveness of Community vs Hospital Eye Service (ECHoES) trial is a virtual trial; lesion reactivation decisions were made about vignettes that comprised clinical data, colour fundus photographs, and optical coherence tomograms displayed on a web-based platform. Participants were either hospital ophthalmologists or community optometrists. All participants were provided with webinar training on the disease, its management, and assessment of the retinal imaging outputs. In a balanced design, 96 participants each assessed 42 vignettes; a total of 288 vignettes were assessed seven times by each professional group.The primary outcome is a participant's judgement of lesion reactivation compared with a reference standard. Secondary outcomes are the frequency of sight threatening errors; judgements about specific lesion components; participant-rated confidence in their decisions about the primary outcome; cost effectiveness of follow-up by optometrists rather than ophthalmologists.

Discussion
This trial addresses an important question for the NHS, namely whether, with appropriate training, community optometrists can make retreatment decisions for patients with nAMD to the same standard as hospital ophthalmologists. The trial employed a novel approach as participation was entirely through a web-based application; the trial required very few resources compared with those that would have been needed for a conventional randomised controlled clinical trial.

Molecular Subtypes and Personalized Therapy in Metastatic Colorectal Cancer

Development of colorectal cancer occurs via a number of key pathways, with the clinicopathological features of specific subgroups being driven by underlying molecular changes. Mutations in key genes within the network of signalling pathways have been identified; however, therapeutic strategies to target these aberrations remain limited. As understanding of the biology of colorectal cancer has improved, this has led to a move toward broader genomic testing, collaborative research and innovative, adaptive clinical trial design. Recent developments in therapy include the routine adoption of wider mutational spectrum testing prior to use of targeted therapies and the first promise of effective immunotherapy for colorectal cancer patients. This review details current biomarkers in colorectal cancer for molecular stratification and for treatment allocation purposes, including open and planned precision medicine trials. Advances in our understanding, therapeutic strategy and technology will also be outlined.

Inappropriate medication use in long-term care facility residents with advanced Alzheimer’s disease and other dementias

Les personnes atteintes de démence sévère, résidant dans un centre d’hébergement et de soins de longue durée (CHSLD) et approchant la fin de leur vie, ne reçoivent pas systématiquement des soins palliatifs, malgré que ce niveau de soins soit le plus approprié. La plupart de ces personnes reçoivent également un grand nombre de médicaments dont les effets indésirables peuvent contribuer à des souffrances évitables. Une approche axée sur les soins palliatifs serait possiblement associée à une réduction de la charge médicamenteuse et, du même coup, à une prescription plus appropriée. Les objectifs de ce projet de recherche étaient de décrire l’usage des médicaments chez les résidents atteints de démence sévère en CHSLD, de comparer leur usage de médicaments à des critères de pertinence et d’évaluer si la mise en œuvre d’une approche axée sur les soins palliatifs était associée aux médicaments prescrits. Cette étude décrit l’usage des médicaments chez 215 sujets atteints de démence sévère et en fin de vie qui ont participé à une étude d’intervention quasi expérimentale menée dans quatre CHSLD du Québec sur la mise en œuvre d’une approche axée sur les soins palliatifs. L’utilisation des médicaments a été comparée à trois listes de critères pertinents publiés, soit ceux de Holmes, Rancourt et Kröger, en utilisant des statistiques descriptives. Les analyses sur l’usage de 412 médicaments différents chez 120 sujets du groupe expérimental et 95 sujets du groupe témoin ont montré que cette approche axée sur les soins palliatifs n’est pas associée à une prescription plus appropriée des médicaments chez ces personnes particulièrement vulnérables.

Topical bacteriophage therapy of the infected diabetic foot

Tese de doutoramento, Medicina (Medicina Interna), Universidade de Lisboa, Faculdade de Medicina, 2014

Telaprevir or boceprevir based therapy for chronic hepatitis C infection: Development of resistance-associated variants in treatment failure

The use of triple-therapy, pegylated-interferon, ribavirin and either of the first generation hepatitis C virus (HCV) protease inhibitors telaprevir or boceprevir, is the new standard of care for treating genotype 1 chronic HCV. Clinical trials have shown response rates of around 70–80%, but there is limited data from the use of this combination outside this setting. Through an expanded access programme, we treated 59 patients, treatment naïve and experienced, with triple therapy. Baseline factors predicting treatment response or failure during triple therapy phase were identified in 58 patients. Thirty seven (63.8%) of 58 patients had undetectable HCV RNA 12 weeks after the end of treatment. Genotype 1a (p = 0.053), null-response to previous treatment (p = 0.034), the rate of viral load decline after 12 weeks of previous interferon-based treatment (p = 0.033) were all associated with triple-therapy failure. The most common cause of on-treatment failure for telaprevir-based regimens was the development of resistance-associated variants (RAVs) at amino acids 36 and/or 155 of HCV protease (p = 0.027) whereas in boceprevir-based regimens mutations at amino acid 54 were significant (p = 0.015). SVR12 rates approaching 64% were achieved using triple therapy outside the clinical trial setting, in a patient cohort that included cirrhotics.

Key-elements of family interventions for psychosis : a qualitative research

RESUMO:As perturbações psicóticas são doenças mentais complexas sendo influenciadas na sua etiologia e prognóstico por factores biológicos e psicossociais. A interferência do ambiente familiar na evolução da doença espelha bem esta realidade. Quando em 1962 George Brown e colaboradores descobriram que ambientes familiares com elevada Emoção Expressa (EE) contribuíam para um aumento significativo do número de recaídas de pessoas com esquizofrenia (Brown et al., 1962), estava aberto o caminho para o desenvolvimento de novas intervenções familiares. A EE inclui cinco componentes: três componentes negativos, i.e. criticismo, hostilidade e envolvimento emocional excessivo; e dois componentes positivos, i.e. afectividade e apreço (Amaresha & Venkatasubramanian, 2012; Kuipers et al., 2002). No final dos anos 1970 surgiram os primeiros trabalhos na área das intervenções familiares nas psicoses (IFP). Dois grupos em países diferentes, no Reino Unido e nos Estados Unidos da América, desenvolveram quase em simultâneo duas abordagens distintas. Em Londres, a equipa liderada por Julian Leff desenhava uma intervenção combinando sessões unifamiliares em casa, incluindo o paciente, e sessões em grupo, apenas para os familiares (Leff et al., 1982). Por seu turno, em Pittsburgh, Gerard Hogarty e colaboradores desenvolviam uma abordagem que compreendia a dinamização de sessões educativas em grupo (Anderson e tal., 1980). Para designar este trabalho, Hogarty e colaboradores propuseram o termo “psicoeducação”. As IFP começaram a ser conhecidas por esta designação que se generalizou até aos dias de hoje. Neste contexto a educação era vista como a partilha de informação acerca da doença, dos profissionais para os familiares. Nas sessões os profissionais eram informados acerca das manifestações, etiologia, tratamento e evolução das psicoses, bem como de formas para lidar com as situações difíceis geradas pela doença, e.g. risco de recaída. Os trabalhos pioneiros das IFP foram rapidamente sucedidos pelo desenvolvimento de novos modelos e a proliferação de estudos de eficácia. Para além dos modelos de Leff e Hogarty, os modelos IFP que ficaram mais conhecidos foram: (1) a Terapia Familiar-Comportamental, desenvolvida por Ian Falloon e colaboradores (Falloon et al., 1984); e (2) a Terapia Multifamiliar em Grupo, desenvolvida por William McFarlane e colaboradores (McFarlane, 1991). O incremento de estudos de eficácia contribuiu rapidamente para as primeiras meta-análises. Estas, por sua vez, resultaram na inclusão das IFP nas normas de orientação clínica mais relevantes para o tratamento das psicoses, nomeadamente da esquizofrenia (e.g. PORT Recomendations e NICE Guidelines). No geral os estudos apontavam para uma diminuição do risco de recaída na esquizofrenia na ordem dos 20 a 50% em dois anos (Pitschel-Walz et al., 2001). No final dos anos 1990 as IFP atingiam assim o apogeu. Contudo, a sua aplicação prática tem ficado aquém do esperado e as barreiras à implementação das IFP passaram a ser o foco das atenções (Gonçalves-Pereira et al., 2006; Leff, 2000). Simultaneamente, alguns autores começaram a levantar a questão da incerteza sobre quais os elementos-chave da intervenção. O conhecimento sobre o processo das IFP era reduzido e começaram a surgir as primeiras publicações sobre o assunto (Lam, 1991). Em 1997 foi dinamizada uma reunião de consenso entre os três investigadores mais relevantes do momento, Falloon, Leff e McFarlane. Deste encontro promovido pela World Schizophrenia Fellowship for Schizophrenia and Allied Disorders surgiu um documento estabelecendo dois objectivos e quinze princípios para as IFP (WFSAD, 1997). Não obstante os contributos que foram feitos, continua a existir uma grande falta de evidência empírica acerca do processo das IFP e dos seus elementos-chave (Cohen et al., 2008; Dixon et al., 2001; Lam, 1991; Leff, 2000; McFarlane et al., 2003). Também em Portugal, apesar da reflexão teórica nesta área e do registo de ensaios de efectividade de grupos para familiares – estudo FAPS (Gonçalves-Pereira, 2010), os componentes fundamentais das IFP nunca foram analisados directamente. Assim, o projecto de investigação descrito nesta tese teve como objectivo identificar os elementos-chave das IFP com base em investigação qualitativa. Para tal, conduzimos três estudos que nos permitiriam alcançar dados empíricos sobre o tema. O primeiro estudo (descrito no Capítulo 2) consistiu na realização de uma revisão sistemática da literatura científica acerca das variáveis relacionadas com o processo das IFP. A nossa pesquisa esteve focada essencialmente em estudos qualitativos. Contudo, decidimos não restringir demasiado os critérios de inclusão tendo em conta as dificuldades em pesquisar sobre investigação qualitativa nas bases de dados electrónicas e também devido ao facto de ser possível obter informação sobre as variáveis relacionadas com o processo a partir de estudos quantitativos. O método para este estudo foi baseado no PRISMA Statement para revisões sistemáticas da literatura. Depois de definirmos os critérios de inclusão e exclusão, iniciámos várias pesquisas nas bases de dados electrónicas utilizando termos booleanos, truncações e marcadores de campo. Pesquisámos na PubMed/MEDLINE, Web of Science e nas bases de dados incluídas na EBSCO Host (Academic Search Complete; Education Research Complete; Education Source; ERIC; and PsycINFO). As pesquisas geraram 733 resultados. Depois de serem removidos os duplicados, 663 registos foram analisados e foram seleccionados 38 artigos em texto integral. No final, 22 artigos foram incluídos na síntese qualitativa tendo sido agrupados em quatro categorias: (1) estudos examinando de forma abrangente o processo; (2) estudos acerca da opinião dos participantes sobre a intervenção que receberam; (3) estudos comparativos que individualizaram variáveis sobre o processo; e (4) estudos acerca de variáveis mediadoras. Os resultados evidenciaram um considerável hiato na investigação em torno do processo das IFP. Identificámos apenas um estudo que abordava de forma abrangente o processo das IFP (Bloch, et al., 1995). Este artigo descrevia uma análise qualitativa de um estudo experimental de uma IFP. Contudo, as suas conclusões gerais revelaramse pobres e apenas se podia extrair com certeza de que as IFP devem ser baseadas nas necessidades dos participantes e que os terapeutas devem assumir diferentes papéis ao longo da intervenção. Da revisão foi possível perceber que os factores terapêuticos comuns como a aliança terapêutica, empatia, apreço e a “aceitação incondicional”, podiam ser eles próprios um elemento isolado para a eficácia das IFP. Outros estudos enfatizaram a educação como elemento chave da intervenção (e.g. Levy-Frank et al., 2011), ao passo que outros ainda colocavam a ênfase no treino de estratégias para lidar com a doença i.e. coping (e.g. Tarrier et al., 1988). Com base nesta diversidade de resultados e tendo em conta algumas propostas prévias de peritos (McFarlane, 1991; Liberman & Liberman, 2003), desenvolvemos a hipótese de concebermos as IFP como um processo por etapas, de acordo com as necessidades dos familiares. No primeiro nível estariam as estratégias relacionadas com os factores terapêuticos comuns e o suporte emocional,no segundo nível a educação acerca da doença, e num nível mais avançado, o foco seria o treino de estratégias para lidar com a doença e diminuir a EE. Neste estudo concluímos que nem todas as famílias iriam precisar de IFP complexas e que nesses casos seria possível obter resultados favoráveis com IFP pouco intensas. O Estudo 2 (descrito no Capítulo 3) consistiu numa análise qualitativa dos registos clínicos do primeiro ensaio clínico da IFP de Leff e colaboradores (Leff et al., 1982). Este ensaio clínico culminou numa das evidências mais substanciais alguma vez alcançada com uma IFP (Leff et al., 1982; Leff et al., 1985; Pitschel-Walz et al., 2001). Este estudo teve como objectivo modular a EE recorrendo a um modelo misto com que compreendia sessões familiares em grupo e algumas sessões unifamiliares em casa, incluindo o paciente. Os resultados mostraram uma diminuição das recaídas em nove meses de 50% no grupo de controlo para 8% no grupo experimental. Os registos analisados neste estudo datam do período de 1977 a 1982 e podem ser considerados como material histórico de alto valor, que surpreendentemente nunca tinha sido analisado. Eram compostos por descrições pormenorizadas dos terapeutas, incluindo excertos em discurso directo e estavam descritos segundo uma estrutura, contendo também os comentários dos terapeutas. No total os registos representavam 85 sessões em grupo para familiares durante os cinco anos do ensaio clínico e 25 sessões unifamiliares em casa incluindo o paciente. Para a análise qualitativa decidimos utilizar um método de análise dedutivo, com uma abordagem mecânica de codificação dos registos em categorias previamente definidas. Tomámos esta decisão com base na extensão apreciável dos registos e porque tínhamos disponível informação válida acerca das categorias que iríamos encontrar nos mesmos, nomeadamente a informação contida no manual da intervenção, publicado sob a forma de livro, e nos resultados da 140 nossa revisão sistemática da literatura (Estudo 1). Deste modo, foi construída uma grelha com a estrutura de codificação, que serviu de base para a análise, envolvendo 15 categorias. De modo a cumprir com critérios de validade e fidelidade rigorosos, optámos por executar uma dupla codificação independente. Deste modo dois observadores leram e codificaram independentemente os registos. As discrepâncias na codificação foram revistas até se obter um consenso. No caso de não ser possível chegar a acordo, um terceiro observador, mais experiente nos aspectos técnicos das IFP, tomaria a decisão sobre a codificação. A análise foi executada com recurso ao programa informático NVivo® versão 10 (QSR International). O número de vezes que cada estratégia foi utilizada foi contabilizado, especificando a sessão e o participante. Os dados foram depois exportados para uma base de dados e analisados recorrendo ao programa informático de análise estatística SPSS® versão 20 (IBM Corp.). Foram realizadas explorações estatísticas para descrever os dados e obter informação sobre possíveis relações entre as variáveis. De modo a perceber a significância das observações, recorremos a testes de hipóteses, utilizando as equações de estimação generalizadas. Os resultados da análise revelaram que as estratégias terapêuticas mais utilizadas na intervenção em grupo foram: (1) a criação de momentos para ouvir as necessidades dos participantes e para a partilha de preocupações entre eles – representando 21% de todas as estratégias utilizadas; (2) treino e aconselhamento acerca de formas para lidar com os aspectos mais difíceis da doença – 15%; (3) criar condições para que os participantes recebam suporte emocional – 12%; (4) lidar com o envolvimento emocional excessivo 10%; e (5) o reenquadramento das atribuições dos familiares acerca dos comportamentos dos pacientes – 10%. Nas sessões unifamiliares em casa, as estratégias mais utilizadas foram: (1) lidar com o envolvimento emocional excessivo – representando 33% de todas as estratégias utilizadas nas sessões unifamiliares em casa; (2) treino e aconselhamento acerca de formas para lidar com os aspectos desafiadores da doença – 22%; e (3) o reenquadramento das atribuições dos familiares acerca dos comportamentos dos pacientes, juntamente com o lidar com a zanga, o conflito e a rejeição – ambas com 10%. A análise longitudinal mostrou que a criação de momentos para ouvir as necessidades dos familiares tende a acontecer invariavelmente ao longo do programa. Sempre que isso acontece, são geralmente utilizadas estratégias para ajudar os familiares a lidarem melhor com os aspectos difíceis da doença e estratégias para fomentar o suporte emocional. Por sua vez, foi possível perceber que o trabalho para diminuir o envolvimento emocional excessivo pode acontecer logo nas primeiras sessões. O reenquadramento e o lidar com a zanga/ conflito/ rejeição tendem a acontecer a partir da fase intermédia até às últimas sessões. A análise das diferenças entre os familiares com baixa EE e os de elevada EE, mostrou que os familiares com elevada EE tendem a tornar-se o foco da intervenção grupal. Por sua vez, os familiares com baixa EE recebem mais estratégias relacionadas com aliança terapêutica, comparativamente com os familiares com elevada EE. São de realçar os dados relativamente às estratégias educativas. Foi possível observar que estas tendem a acontecer mais no início dos grupos, não estando associadas a outras estratégias. Contudo é de notar a sua baixa utilização, a rondar apenas os 5%.O Estudo 3 (descrito no Capítulo 4) surgiu como uma forma de completar a análise do Estudo 2, permitindo uma visão mais narrativa do processo e focando, adicionalmente, as mudanças que ocorrem nos participantes. Com base nos mesmos registos utilizados no Estudo 2, codificámos de forma secundária os registos em duas categorias i.e. marcadores de mudança e marcadores emocionais. Os marcadores de mudança foram cotados sempre que um participante exibia comportamentos ou pensamentos diferentes dos anteriores no sentido de uma eventual redução na EE. Os marcadores emocionais correspondiam à expressão intensa de sentimentos por parte dos participantes nas sessões e que estariam relacionados com assuntos-chave para essas pessoas. Os excertos que continham a informação destes marcadores foram posteriormente revistos e articulados com notas e comentários não estruturados que recolhemos durante a codificação do Estudo 2. Com base nesta informação os registos foram revistos e, utilizando um método indutivo, elaborámos uma narrativa acerca da intervenção. Os resultados da narrativa foram discutidos com dados de que dispúnhamos, referentes a reuniões com os terapeutas envolvidos na intervenção em análise (Elizabeth Kuipers, Ruth Berkowitz e Julian Leff; Londres, Novembro de 2011). Reconhecemos que, pela sua natureza não estruturada e indutiva, a avaliação narrativa está mais sujeita ao viés de observador. Não obstante, os resultados deste Estudo 3 parecem revestir uma consistência elevada. O mais relevante foi a evidência de que na intervenção em análise ocorreram mudanças emocionais significativas nos familiares ao longo das sessões em grupo. Numa fase inicial os familiares tenderam a expressar sentimentos de zanga. Seguidamente, os terapeutas iam nterrompendo o discurso de reminiscências, direccionavam o discurso para as suas preocupações actuais e os familiares pareciam ficar mais calmos. Contudo, à medida que os 143 participantes “mergulhavam” nos problemas com que se confrontavam na altura, os sentimentos de zanga davam lugar a sentimentos de perda e angústia. Nessa altura os terapeutas enfatizavam o suporte emocional e introduziam progressivamente técnicas de reenquadramento para ajudar os participantes a avaliar de forma mais positiva as situações. Este trabalho dava lugar a sentimentos mais positivos, como a aceitação, apreço e a sensação de controlo. O Estudo 3 evidenciou também o que designamos como o “Efeito de Passagem de Testemunho”. Este efeito aconteceu sempre que um membro novo se juntava ao grupo. Os membros antigos, que estavam a ser o alvo das atenções e naturalmente a receber mais intervenção, mudam de papel e passam eles próprios a focar as suas atenções nos membros mais recentes do grupo, contribuindo para a dinâmica do grupo com as mesmas intervenções que os ajudaram previamente. Por exemplo, alguns membros antigos que eram altamente críticos nos grupos em relação aos seus familiares passavam a fazer comentários de reenquadramento dirigidos para os novos membros. Por fim, o Capítulo 5 resume as conclusões gerais deste projecto de investigação. Os estudos apresentados permitiram um incremento no conhecimento acerca do processo das IFP. Anteriormente esta informação era baseada sobretudo na opinião de peritos. Com este projecto aumentámos o nível de evidência ao apresentar estudos com base em dados empíricos. A análise qualitativa do Estudo 2 permitiu pela primeira vez, tanto quanto é do nosso conhecimento, perceber de forma aprofundada o processo subjacente a uma IFP (no contexto de um ensaio clínico que se revelou como um dos mais eficazes de sempre). Identificámos as estratégias mais utilizadas, as relações entre elas e a sua diferente aplicação entre familiares com baixa EE e familiares com alta EE.O Estudo 3 completou a informação incluindo aspectos relacionados com as mudanças individuais durante o programa. No final foi possível perceber que as IFP devem ser um programa por etapas. Nos Estudo 2 e 3, evidenciámos que numa fase inicial, os terapeutas dedicaram especial atenção para que os familiares tivessem espaço para partilharem as suas necessidades, disponibilizando logo de seguida estratégias para promover o suporte emocional e estratégias de coping. Num nível subsequente do programa, o trabalho terapêutico avançou para estratégias mais direccionadas para regular a EE, mantendo sempre as estratégias iniciais ao longo das sessões. Assim apesar de a educação ter sido um componente importante na IFP em análise, houve outras estratégias mais relevantes no processo. A evidência gerada pelos Estudos 2 e 3 baseou-se em registos históricos de elevado valor, sendo que os constructos subjacentes na época, nomeadamente a EE, continuam a ser a base da investigação e prática das IFP a nível mundial em diferentes culturas (Butzlaff & Hooley, 1998). Concluímos que as IFP são um processo complexo com diferentes níveis de intervenção, podendo gerar mudanças emocionais nos participantes durante as sessões. No futuro será importante replicar o nosso trabalho (nomeadamente o Estudo 2) com outras abordagens de IFP, de modo a obter informação acerca do seu processo. Esse conhecimento será fundamental para uma possível evolução do paradigma das IFP. ----------- ABSTRACT: Background: Psychotic-spectrum disorders are complex biopsychosocial conditions and family issues are important determinants of prognosis. The discovery of the influence of expressed emotion on the course of schizophrenia paved the road to the development of family interventions aiming to lower the “emotional temperature” in the family. These treatment approaches became widely recognised. Effectiveness studies showed remarkable and strong results in relapse prevention and these interventions were generalised to other psychotic disorders besides schizophrenia. Family interventions for psychosis (FIP) prospered and were included in the most important treatment guidelines. However, there was little knowledge about the process of FIP. Different FIP approaches all led to similar outcomes. This intriguing fact caught the attention of authors and attempts were made to identify the key-elements of FIP. Notwithstanding, these efforts were mainly based on experts’ opinions and the conclusions were scanty. Therefore, the knowledge about the process of FIP remains unclear. Aims: To find out which are the key-elements of FIP based on empirical data. Methods: Qualitative research. Three studies were conducted to explore the process of FIP and isolate variables that allowed the identification of the key-elements of FIP. Study 1 consisted of a systematic literature review of studies evaluating process-related variables of FIP. Study 2 subjected the intervention records of a formerly conducted effective clinical trial of FIP to a qualitative analysis. Records were analysed into categories and the emerging data were explored using descriptive statistics and generalised estimating equations. Study 3 consisted of a narrative evaluation using an inductive qualitative approach, examining the same data of Study 2. Emotional markers and markers of change were identified in the records and the content of these excerpts was synthesised and discussed. Results: On Study 1, searches revealed 733 results and 22 papers were included in the qualitative synthesis. We found a single study comprehensively exploring the process of FIP. All other studies focused on particular aspects of the process-related variables. The key-elements of FIP seemed to be the so-called “common therapeutic factors”, followed by education about the illness and coping skills training. Other elements were also identified, as the majority of studies evidenced a multiple array of components. Study 2,revealed as the most used strategies in the intervention programme we analysed: the addressing of needs; sharing; coping skills and advice; emotional support; dealing with overinvolvement; and reframing relatives’ views about patients’ behaviours. Patterns of the usefulness of the strategies throughout the intervention programme were identified and differences between high expressed emotion and low expressed emotion relatives were elucidated. Study 3 accumulated evidence that relatives experience different emotions during group sessions, ranging from anger to grief, and later on, to acceptance and positive feelings. Discussion: Study 1 suggested a stepped model of intervention according to the needs of the families. It also revealed a gap in qualitative research of FIP. Study 2 demonstrated that therapists of the trial under analysis often created opportunities for relatives to express and share their concerns throughout the entire treatment programme. The use of this strategy was immediately followed by coping skills enhancement, advice and emotional support. Strategies aiming to deal with overinvolvement may also occur early in the treatment programme. Reframing was the next most used strategy, followed by dealing with anger, conflict and rejection. This middle and later work seems to operate in lowering criticism and hostility, while the former seems to diminish overinvolvement. Single-family sessions may be used to augment the work developed in the relatives groups. Study 3 revealed a missing part of Study 2. It demonstrated that the process of FIP promotes emotional changes in the relatives and therapists must be sensitive to the emotional pathway of each participant in the group.

Pharmacokinetics and safety of panobacumab: specific adjunctive immunotherapy in critical patients with nosocomial Pseudomonas aeruginosa O11 pneumonia.

Objectives Nosocomial Pseudomonas aeruginosa pneumonia remains a major concern in critically ill patients. We explored the potential impact of microorganism-targeted adjunctive immunotherapy in such patients. Patients and methods This multicentre, open pilot Phase 2a clinical trial (NCT00851435) prospectively evaluated the safety, pharmacokinetics and potential efficacy of three doses of 1.2 mg/kg panobacumab, a fully human monoclonal anti-lipopolysaccharide IgM, given every 72 h in 18 patients developing nosocomial P. aeruginosa (serotype O11) pneumonia. Results Seventeen out of 18 patients were included in the pharmacokinetic analysis. In 13 patients receiving three doses, the maximal concentration after the third infusion was 33.9 ± 8.0 μg/mL, total area under the serum concentration-time curve was 5397 ± 1993 μg h/mL and elimination half-life was 102.3 ± 47.8 h. Panobacumab was well tolerated, induced no immunogenicity and was detected in respiratory samples. In contrast to Acute Physiology and Chronic Health Evaluation II (APACHE II) prediction, all 13 patients receiving three doses survived, with a mean clinical resolution in 9.0 ± 2.7 days. Two patients suffered a recurrence at days 17 and 20. Conclusions These data suggest that panobacumab is safe, with a pharmacokinetic profile similar to that in healthy volunteers. It was associated with high clinical cure and survival rates in patients developing nosocomial P. aeruginosa O11 pneumonia. We concluded that these promising results warrant further trials.